Armed with $55M in Third Rock cash, Goldfinch Bio sets out to build a kidney disease pipeline
Three years ago, Peter Mundel at Harvard Medical School published an intriguing study in the New England Journal of Medicine that highlighted the
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
